Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Alberto Lleo*, Daniel Alcolea, Pablo Martinez-Lage, Philip Scheltens, Lucilla Parnetti, Judes Poirier, Anja H. Simonsen, Marcel M. Verbeek, Pedro Rosa-Neto, Rosalinde E. R. Slot, Mikel Tainta, Andrea Izaguirre, Babette L. R. Reijs, Lucia Farotti, Magda Tsolaki, Rik Vandenbergue, Yvonne Freund-Levi, Frans R. J. Verhey, Jordi Clarimon, Juan ForteaLutz Frolich, Isabel Santana, Jose Luis Molinuevo, Sylvain Lehmann, Pieter J. Visser, Charlotte E. Teunissen, Henrik Zetterberg, Kaj Blennow

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)742-753
Number of pages12
JournalAlzheimer's & Dementia
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 2019

Keywords

  • Alzheimer
  • CSF
  • Tau
  • Amyloid
  • Neurofilaments
  • Inflammation
  • YKL-40
  • NEUROFILAMENT LIGHT
  • ASSOCIATION WORKGROUPS
  • DIAGNOSTIC GUIDELINES
  • NATIONAL INSTITUTE
  • CSF BIOMARKERS
  • TAU LEVELS
  • RECOMMENDATIONS
  • PROTEIN
  • BETA
  • DEMENTIA

Cite this

Lleo, A., Alcolea, D., Martinez-Lage, P., Scheltens, P., Parnetti, L., Poirier, J., Simonsen, A. H., Verbeek, M. M., Rosa-Neto, P., Slot, R. E. R., Tainta, M., Izaguirre, A., Reijs, B. L. R., Farotti, L., Tsolaki, M., Vandenbergue, R., Freund-Levi, Y., Verhey, F. R. J., Clarimon, J., ... Blennow, K. (2019). Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's & Dementia, 15(6), 742-753. https://doi.org/10.1016/j.jalz.2019.01.015